Following the successful demonstration of the safety and clinical suitability of our red biocompatible CFQD® quantum dots (VivodotsTM nanoparticles), the Life Sciences team, supported by Innovate UK grants, pursued several unique applications related to photodynamic therapy and medical imaging. Preclinical translational studies were continued in vitro and in vivo to confirm effectiveness in the diagnosis and treatment of skin, pancreatic and colorectal cancers. Newly developed targeting ligands are being evaluated with very promising results. We have also enhanced our business reach and networking and made our productised VivodotsTM brand available for sales to interested customers. As always, our goal is to unlock the potential of our biocompatible quantum dots and develop nano diagnostics and therapeutics that can truly answer unmet medical needs.
- Cancer overtakes CVD as leading cause of death in wealthy nations (Medscape Medical News, 4 Sep 2019)
- The global cancer diagnostics market size was valued at USD 144.4 billion in 2018 and a CAGR of 7.0% (Market Research Report, Grand View Research, Feb 2019)